Your browser doesn't support javascript.
Breastfeeding Mother and Child Clinical Outcomes After COVID-19 Vaccination.
Low, Jia Ming; Lee, Le Ye; Ng, Yvonne Peng Mei; Zhong, Youjia; Amin, Zubair.
  • Low JM; Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Lee LY; Department of Neonatology, Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore.
  • Ng YPM; Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Zhong Y; Department of Neonatology, Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore.
  • Amin Z; Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
J Hum Lact ; 38(1): 37-42, 2022 02.
Article in English | MEDLINE | ID: covidwho-1488357
ABSTRACT

BACKGROUND:

Pre-approval clinical trials of the Pfizer/BioNTech messenger RNA COVID-19 vaccine, BNT162b2 did not include participants who were breastfeeding. Therefore, there is limited evidence about outcomes of breastfeeding mother-child dyads and effects on breastfeeding after vaccination. RESEARCH

AIMS:

To determine (1) solicited adverse effects (e.g., axillary lymphadenopathy, mastitis, and breast engorgement), which are unique to lactating individuals; and (2) systemic and local adverse effects of COVID-19 mRNA vaccine on mothers and potential effects on their breastfed infants.

METHOD:

This was a prospective cohort study of lactating healthcare workers (N = 88) in Singapore who received two doses of BNT162b2 vaccination (Pfizer/BioNTech). The outcomes of mother-child dyads within 28 days after the second vaccine dose were determined through a participant-completed questionnaire.

RESULTS:

Minimal effects related to breastfeeding were reported by this cohort; three of 88 (3.4%) participants had mastitis, one (1.1%) participant experienced breast engorgement, five of 88 (5.7%) participants reported cervical or axillary lymphadenopathy. There was no change in human milk supply after vaccination. The most common side effect was pain/redness/swelling at the injection site, which was experienced by 57 (64.8%) participants. There were no serious adverse events of anaphylaxis or hospital admissions. There were no short-term adverse effects reported in the infants of 67 lactating participants who breastfed within 72 hr after BNT162b2 vaccination.

CONCLUSIONS:

BNT162b2 vaccination was well tolerated in lactating participants and was not associated with short-term adverse effects in their breastfed infants. STUDY PROTOCOL REGISTRATION The study protocol was registered at clinicaltrials.gov (NCT04802278).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Clinical Practice Guide / Observational study / Risk factors Topics: Vaccines Limits: Female / Humans / Infant Language: English Journal: J Hum Lact Journal subject: Nursing / Obstetrics Year: 2022 Document Type: Article Affiliation country: 08903344211056522

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Clinical Practice Guide / Observational study / Risk factors Topics: Vaccines Limits: Female / Humans / Infant Language: English Journal: J Hum Lact Journal subject: Nursing / Obstetrics Year: 2022 Document Type: Article Affiliation country: 08903344211056522